Key Highlights
- Through ARKK ETF, ARK Invest liquidated 19,491 AMD shares valued at approximately $9.9 million
- ARK purchased 575,700 Archer Aviation shares totaling $3.4 million, expanding exposure to electric air taxi technology
- ARK accumulated 93,290 Cerebras Systems shares worth $17.2 million as the stock declined 32.4% from its May peak
- Cerebras delivered Q2 revenue of $209.9 million, representing 103% annual growth with cloud segment surging 287%
- ARK divested $6.5 million in Palantir Technologies while increasing holdings in Beam Therapeutics and CRISPR Therapeutics
On September 9, 2026, Cathie Wood’s ARK Invest executed a series of significant portfolio adjustments, exiting several prominent technology holdings while amplifying stakes in artificial intelligence infrastructure and biotechnology companies.
The most substantial divestment involved Advanced Micro Devices. Through the ARKK ETF, ARK disposed of 19,491 shares representing approximately $9.9 million in value. This transaction extends ARK’s week-long trend of scaling back its AMD exposure.
Advanced Micro Devices, Inc., AMD
Additionally, ARK liquidated 38,395 Palantir Technologies shares valued at $6.5 million and reduced its Tempus AI holdings by offloading 68,759 shares worth $4.4 million.
Regarding acquisitions, ARK secured 575,700 Archer Aviation shares for $3.4 million. Archer specializes in electric vertical takeoff and landing aircraft, and this transaction reinforces ARK’s confidence in the emerging urban air mobility sector.
Major Investment in Cerebras Systems
The most significant strategic move involves ARK’s aggressive accumulation of Cerebras Systems shares. On August 25, ARK acquired 93,290 shares distributed across two ETFs, representing approximately $17.2 million at execution prices.
Cerebras stock has experienced considerable headwinds. The shares declined 8% over the previous month and have retreated 32.4% from their May 14 listing price. The downturn accelerated following the company’s August 18 Supernova event, which triggered profit-taking among investors.
Nevertheless, Wood evidently identifies substantial long-term opportunity. Cerebras disclosed Q2 revenue of $209.9 million, representing a 103% increase year-over-year. The cloud segment alone generated $127.7 million, marking a remarkable 287% annual expansion.
Profitability metrics have raised some concerns. Core gross margin registered 40.6% in Q2, declining from 46.5% recorded in Q1. Company leadership attributes this compression to temporary factors, specifically costs associated with leasing back systems from cloud infrastructure partners at elevated rates.
Management anticipates margin recovery by Q4 as internally owned systems become operational. The company maintains a long-term core gross margin target exceeding 60%.
Financial Position and Street Sentiment on Cerebras
Cerebras concluded Q2 with more than $8.6 billion in combined cash, restricted cash, and marketable securities. The company also maintains access to an undrawn $850 million revolving credit facility.
The organization has locked in over 600 megawatts of data center infrastructure, either currently operational or scheduled for deployment by year-end 2027. Manufacturing throughput has quadrupled compared to the first half of 2025.
Within ARK’s portfolio structure, Cerebras represents 2.68% of the ARK Innovation ETF and 2.73% of the ARK Next Generation Internet ETF.
Analyst consensus shows strong conviction, with 8 of 11 covering analysts assigning Strong Buy ratings. The consensus price target of $283.91 suggests potential appreciation of 35.1%, while the most optimistic forecast of $330 implies possible gains of 57.1% over the coming year.
During the same trading session, ARK expanded positions in Beam Therapeutics, CRISPR Therapeutics, and Robinhood Markets, while simultaneously divesting shares of Twist Bioscience and 10X Genomics.


